PGRMC1 as a potential biomarker of breast cancer risk for menopausal hormone therapy

doi:10.3969/j.issn.1006-7795.2025.04.001

Abstract

Abstract: Progesterone receptor membrane component 1 (PGRMC1) is closely related to hormone therapy which belongs to the membrane-associated progesterone receptor (MAPR) family. A large number of in vitro experiments, in vivo animal experiments, clinical samples of breast cancer patients and blood studies showed that all synthetic progesterone (excluding natural progesterone and dydrogesterone) can promote the rapid proliferation of breast cancer cells overexpressing PGRMC1. In patients with breast cancer, PGRMC1 is significantly negatively correlated with tumor grade and prognosis, and PGRMC1 level in blood is positively correlated with PGRMC1 expression in breast cancer tissues, and PGRMC1 is superior to traditional tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen (CA125), and CA153 in predicting early breast cancer. Therefore, PGRMC1 may serve as a predictive marker for identifying an elevated risk of breast cancer associated with menopausal hormone replacement therapy.

Key words: progesterone receptor membrane component 1, progesterone receptor membrane component 1 (PGRMC1), menopausal hormone therapy;breast cancer risk, breast cancer, hormone safety

CLC Number:

R711

Wang Yuejiao, Ruan Xiangyan, Gu Muqing, Wei Yun, Guan Yuwei, Zhao Yue, Alfred O.Mueck. PGRMC1 as a potential biomarker of breast cancer risk for menopausal hormone therapy[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2025.04.001.

References

［1］Parker M, Bucknall M, Jagger C, et al. Population-based estimates of healthy working life expectancy in England at age 50 years: analysis of data from the English longitudinal study of ageing［J］. Lancet Public Health, 2020, 5(7): e395-e403.
［2］陈蓉. 《中国绝经管理与绝经激素治疗指南2023版》解读［J］. 协和医学杂志, 2023, 14(3): 514－519.
［3］Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence［J］. Lancet, 2019, 394(10204): 1159－1168.
［4］阮祥燕, 王月姣. 理性看待绝经激素治疗与乳腺癌发病风险［J］. 协和医学杂志, 2021, 12(2): 163－166.
［5］Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial［J］. JAMA, 2002, 288(3): 321－333.
［6］Chlebowski R T, Anderson G L, Aragaki A K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials［J］. JAMA, 2020, 324(4): 369－380.
［7］Manson J E, Crandall C J, Rossouw J E, et al. The women's health initiative randomized trials and clinical practice:a review［J］. JAMA, 2024, 331(20): 1748－1760.
［8］Ruan X Y, Mueck A O. Clinical importance of PGRMC1 in hormone responsive breast cancer［J］. Breast Care, 2023, 18(3): 172－178.
［9］Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort［J］. Int J Cancer, 2005, 114(3): 448－454.
［10］Mohammed H, Russell I A, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer［J］. Nature, 2015, 523(7560): 313－317.
［11］Ruan X Y, Zhang Y, Mueck A O, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer［J］. Menopause, 2017, 24(2): 203－209.
［12］Zhang L, Ruan X, Gu M, et al. E2+norethisterone promotes the PI3K-AKT pathway via PGRMC1 to induce breast cancer cell proliferation［J］. Climacteric, 2022, 25(5): 467－475.
［13］Bai Y X, Ludescher M, Poschmann G, et al. PGRMC1 promotes progestin-dependent proliferation of breast cancer cells by binding prohibitins resulting in activation of ERα signaling［J］. Cancers, 2021, 13(22): 5635.
［14］Xu X, Ruan X Y, Zhang Y, et al. Comprehensive analysis of the implication of PGRMC1 in triple-negative breast cancer［J］. Front Bioeng Biotechnol, 2021, 9: 714030.
［15］Craven R J. PGRMC1: a new biomarker for the estrogen receptor in breast cancer［J］. Breast Cancer Res, 2008, 10(6): 113.
［16］Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development［J］. Climacteric, 2013, 16(5): 509－513.
［17］Cai G J, Wang Y J, Houda T, et al. MicroRNA-181a suppresses norethisterone-promoted tumorigenesis of breast epithelial MCF10A cells through the PGRMC1/EGFR－PI3K/Akt/mTOR signaling pathway［J］. Transl Oncol, 2021, 14(6): 101068.
［18］Zhao Y, Ruan X, Cheng J, et al. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis［J］. Climacteric, 2023, 26(2): 135－142.
［19］Wang Y, Tahiri H, Yang C, et al. Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer［J］. Climacteric, 2023, 26(1): 64－71.
［20］Gu M Q, Wang L J, Yang C, et al. Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth［J］. Maturitas, 2018, 114: 60－66.
［21］Pedroza D A, Ramirez M, Rajamanickam V, et al. miRNome and functional network analysis of PGRMC1 regulated miRNA target genes identify pathways and biological functions associated with triple negative breast cancer［J］. Front Oncol, 2021, 11: 710337.
［22］Zhang Y, Ruan X Y, Mi X, et al. Expression of PGRMC1 in paraffin-embedded tissues of breast cancer［J］. Int J Clin Exp Pathol, 2017, 10(9): 9639－9643.
［23］Zhang Y, Ruan X Y, Willibald M, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?［J］. Gynecol Endocrinol, 2016, 32(1): 58－60.
［24］Li X, Ruan X, Gu M, et al. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol［J］. Climacteric, 2019, 22(5): 483－488.
［25］Ruan X Y, Mueck A O. Systemic progesterone therapy-oral, vaginal, injections and even transdermal?［J］. Maturitas, 2014, 79(3): 248－255.
［26］赵越, 阮祥燕, 谷牧青, 等. PGRMC1在激素治疗中促进乳腺癌细胞增殖的机制研究［J］. 中国癌症防治杂志, 2022, 14(4): 378－384.
［27］赵越, 阮祥燕. PGRMC1在激素补充治疗中对乳腺癌增殖风险及机制的研究进展［J］. 医学综述, 2022, 28(6): 1097－1102.
［28］Ruan X Y, Gu M Q, Cai G J, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study［J］. Maturitas, 2019, 123: 1－8.
［29］Cai G J, Ruan X Y, Gu M Q, et al. PGRMC1 in animal breast cancer tissue and blood is associated with increased tumor growth with norethisterone in contrast to progesterone and dydrogesterone: four-arm randomized placebo-controlled xenograft study［J］. Gynecol Endocrinol, 2020, 36(11): 1024－1027.
［30］蔡桂举, 阮祥燕. 孕激素受体膜组分1在绝经后激素治疗中乳腺癌风险预测的研究进展［J］. 实用医学杂志, 2021, 37(13): 1769－1773.

[1]	Tian Xuanxuan, Ruan Xiangyan, Zhao Yue, Jin Jing, Liu Shunyu, Jiang Lingling. Effect of individualized lifestyle intervention on sexual function in obese patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2025, 46(4): 614-619.
[2]	Zhao Yue, Ruan Xiangyan, Zou Liying, Ma Jun, Wang Yuejiao, Tian Xuanxuan, Jin Jing. Correlation between thyroid autoimmunity and gestational diabetes mellitus in Chinese euthyroid women [J]. Journal of Capital Medical University, 2025, 46(4): 626-631.
[3]	Ma Jun, Ruan Xiangyan, Xu Zhongting , Zhao Yue , Wang Yuejiao, Alfred O.Mueck, . Clinical efficacy of letrozole combined with Zi Gui Nv Zhen Capsules in patients with PCOS complicated by thin endometrium-induced infertility [J]. Journal of Capital Medical University, 2025, 46(4): 632-636.
[4]	Wang Jing, Zhou Qiaoyun, Wang Muyu, Xiao Yu, Song Dongmei, Guo Yan, Xia Enlan, Li Tinchiu, Huang Xiaowu. Analysis of risk factors and establishment of a prediction model for endometrial cancer in postmenopausal bleeding [J]. Journal of Capital Medical University, 2025, 46(1): 143-149.
[5]	Pei Youjuan, Ruan Xiangyan, Ju Rui, Wang Yuejiao, Jiang Lingling, Ma Jun. The application of artificial intelligence in the reproductive endocrinology [J]. Journal of Capital Medical University, 2024, 45(4): 566-572.
[6]	Li Yanglu, Ruan Xiangyan, Li Yanqiu, Gu Muqing, Du Juan, Wang Zecheng, Cheng Jiaojiao, Jin Fengyu, Jiang Lingling, Yang Yu, Alfred O. Mueck. Protective effect of N-Acetyl-L-Cysteine on cryopreserved-thawed human ovarian tissue [J]. Journal of Capital Medical University, 2024, 45(4): 573-582.
[7]	Wang Zecheng, Ruan Xiangyan, Yang Yu, Li Jing, Alfred O. Mueck. Changes in sexual hormone levels of iatrogenic premature ovarian insufficiency and its impact on glucose metabolism [J]. Journal of Capital Medical University, 2024, 45(4): 583-588.
[8]	Wang Zhikun, Ruan Xiangyan, Liu Lili, Yang Yu, Jiang Lingling, Wang Zecheng, Alfred O.Mueck. The impact of testosterone levels on female sexual function in menopausal transitional and postmenopausal women [J]. Journal of Capital Medical University, 2024, 45(4): 589-595.
[9]	Liu Lili, Ruan Xiangyan, Yang Yu, Jiang Lingling, Wang Zecheng, Zhang Mingzhen, Alfred O.Mueck. Correlation analysis between body composition and lumbar bone mineral density in perimenopausal and postmenopausal women [J]. Journal of Capital Medical University, 2024, 45(4): 596-601.
[10]	Zhao Yue, Ruan Xiangyan, Wang Yuejiao, Ma Jun, Jin Jing. Diagnostic value of multiple androgen indexes measured by LC-MS/MS for polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 602-608.
[11]	Tian Xuanxuan, Ruan Xiangyan, Jin Jing, Ju Rui, Du Juan, Cheng Jiaojiao, Yang Yu. Analysis of sexual function of patients with polycystic ovary syndrome with different clinical phenotypes [J]. Journal of Capital Medical University, 2024, 45(4): 616-622.
[12]	Jiang Lingling, Ruan Xiangyan, Li Yanqiu, Zhang Mingzhen, Wang Zecheng, Yang Yu , Liu Lili, Alfred O. Mueck. The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 623-628.
[13]	Du Juan, Ruan Xiangyan. New progresses in ovarian tissue cryopreservation and transplantation [J]. Journal of Capital Medical University, 2024, 45(4): 629-635.
[14]	. [J]. Journal of Capital Medical University, 2023, 44(5): 695-703.
[15]	Wu Jianhong, Tian Yucui, Jiang Ziwen, Tang Shiqian, Liu Zhaohui, Dai Yinmei. The effect of lncRNA FAM95B1 on the pathogenesis of intrauterine adhesion by regulating insulin-like growth factor 2 [J]. Journal of Capital Medical University, 2023, 44(5): 821-827.